» Articles » PMID: 32444495

Disruption of Profilin1 Function Suppresses Developmental and Pathological Retinal Neovascularization

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2020 May 24
PMID 32444495
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Angiogenesis-mediated neovascularization in the eye is usually associated with visual complications. Pathological angiogenesis is particularly prominent in the retina in the settings of proliferative diabetic retinopathy, in which it can lead to permanent loss of vision. In this study, by bioinformatics analyses, we provide evidence for elevated expression of actin-binding protein PFN1 (profilin1) in the retinal vascular endothelial cells (VECs) of individuals with proliferative diabetic retinopathy, findings further supported by gene expression analyses for PFN1 in experimentally induced abnormal retinal neovascularization in an oxygen-induced retinopathy murine model. We observed that in a conditional knockout mouse model, postnatal deletion of the gene in VECs leads to defects in tip cell activity (marked by impaired filopodial protrusions) and reduced vascular sprouting, resulting in hypovascularization during developmental angiogenesis in the retina. Consistent with these findings, an investigative small molecule compound targeting the PFN1-actin interaction reduced random motility, proliferation, and cord morphogenesis of retinal VECs and experimentally induced abnormal retinal neovascularization In summary, these findings provide the first direct evidence that PFN1 is required for formation of actin-based protrusive structures and developmental angiogenesis in the retina. The proof of concept of susceptibility of abnormal angiogenesis to small molecule intervention of PFN1-actin interaction reported here lays a conceptual foundation for targeting PFN1 as a possible strategy in angiogenesis-dependent retinal diseases.

Citing Articles

Cell and molecular targeted therapies for diabetic retinopathy.

Reddy S, Devi V, Seetharaman A, Shailaja S, Bhat K, Gangaraju R Front Endocrinol (Lausanne). 2024; 15:1416668.

PMID: 38948520 PMC: 11211264. DOI: 10.3389/fendo.2024.1416668.


Haplo-insufficiency of Profilin1 in vascular endothelial cells is beneficial but not sufficient to confer protection against experimentally induced atherosclerosis.

Allen-Gondringer A, Gau D, Dutta P, Roy P Cytoskeleton (Hoboken). 2024; 82(3):81-90.

PMID: 38623956 PMC: 11480255. DOI: 10.1002/cm.21859.


Actin-binding protein profilin1 is an important determinant of cellular phosphoinositide control.

Ricci M, Orenberg A, Ohayon L, Gau D, Wills R, Bae Y J Biol Chem. 2023; 300(1):105583.

PMID: 38141770 PMC: 10826164. DOI: 10.1016/j.jbc.2023.105583.


Vascular endothelial cell-specific disruption of the gene leads to severe multiorgan pathology and inflammation causing mortality.

Allen-Gondringer A, Gau D, Varghese C, Boone D, Stolz D, Larregina A PNAS Nexus. 2023; 2(10):pgad305.

PMID: 37781098 PMC: 10541205. DOI: 10.1093/pnasnexus/pgad305.


Sulfonylpiperazine compounds prevent Plasmodium falciparum invasion of red blood cells through interference with actin-1/profilin dynamics.

Dans M, Piirainen H, Nguyen W, Khurana S, Mehra S, Razook Z PLoS Biol. 2023; 21(4):e3002066.

PMID: 37053271 PMC: 10128974. DOI: 10.1371/journal.pbio.3002066.


References
1.
Stahl A, Connor K, Sapieha P, Chen J, Dennison R, Krah N . The mouse retina as an angiogenesis model. Invest Ophthalmol Vis Sci. 2010; 51(6):2813-26. PMC: 2891451. DOI: 10.1167/iovs.10-5176. View

2.
Stenzel D, Franco C, Estrach S, Mettouchi A, Sauvaget D, Rosewell I . Endothelial basement membrane limits tip cell formation by inducing Dll4/Notch signalling in vivo. EMBO Rep. 2011; 12(11):1135-43. PMC: 3207109. DOI: 10.1038/embor.2011.194. View

3.
Eghoj M, Sorensen T . Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol. 2011; 96(1):21-3. DOI: 10.1136/bjo.2011.203893. View

4.
McAuley A, Sanfilippo P, Hewitt A, Liang H, Lamoureux E, Wang J . Vitreous biomarkers in diabetic retinopathy: a systematic review and meta-analysis. J Diabetes Complications. 2014; 28(3):419-25. DOI: 10.1016/j.jdiacomp.2013.09.010. View

5.
Brown D, Regillo C . Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients. Am J Ophthalmol. 2007; 144(4):627-37. DOI: 10.1016/j.ajo.2007.06.039. View